Drug Profile
OSE 703
Alternative Names: Effi-3; OSE-703Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator OSE Immunotherapeutics
- Developer Memorial Sloan-Kettering Cancer Center; OSE Immunotherapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mesothelioma; Non-small cell lung cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Mesothelioma in France (Parenteral)
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Oct 2021 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in France (Parenteral)